Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saltcal D
- Development stage
- Phase 4
- Lead developer
- Daylon Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Saltcal (marketed as Saltcal D) is an oral nutraceutical supplement developed by Daylon Healthcare Pvt Ltd. It is formulated with 500mg of elemental calcium (derived from calcium carbonate) and 250 IU of Vitamin D3 (cholecalciferol). The product is intended to treat or prevent calcium and vitamin D deficiencies and to support bone health in patients with osteoporosis, osteopenia, rickets, and hypoparathyroidism. It is specifically recommended for postmenopausal women, individuals with high physical activity levels, and those with inadequate dietary intake. The mechanism of action involves direct calcium supplementation to meet physiological requirements and Vitamin D3-mediated enhancement of intestinal calcium absorption.
- Brand names
- SaltcalSaltcal D
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Saltcal D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saltcal D.